Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women.

[1]  I. Ellis,et al.  Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women , 2013, ISRN oncology.

[2]  I. Ellis,et al.  Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women , 2012, Breast Cancer Research and Treatment.

[3]  Jun Zhang,et al.  Mesangial Medium from IgA Nephropathy Patients Induces Podocyte Epithelial-to-mesenchymal Transition through Activation of the Phosphatidyl Inositol-3-kinase/Akt Signaling Pathway , 2012, Cellular Physiology and Biochemistry.

[4]  W. Grizzle,et al.  Ubc9 mediates nuclear localization and growth suppression of BRCA1 and BRCA1a proteins , 2011, Journal of cellular physiology.

[5]  R. Rosell,et al.  mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. , 2011, Journal of the National Cancer Institute.

[6]  Da-Qiang Li,et al.  SUMOylation and SUMO-interacting Motif (SIM) of Metastasis Tumor Antigen 1 (MTA1) Synergistically Regulate Its Transcriptional Repressor Function* , 2011, The Journal of Biological Chemistry.

[7]  C. Gong,et al.  Ubc9 expression predicts chemoresistance in breast cancer , 2011, Chinese journal of cancer.

[8]  D. Jukic,et al.  Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. , 2010, Human pathology.

[9]  I. Ellis,et al.  The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers , 2010, The Journal of pathology.

[10]  I. Ellis,et al.  Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens , 2010, Histopathology.

[11]  Jane Lee,et al.  A Novel Role for Protein Inhibitor of Activated STAT (PIAS) Proteins in Modulating the Activity of Zimp7, a Novel PIAS-like Protein, in Androgen Receptor-mediated Transcription* , 2010, The Journal of Biological Chemistry.

[12]  Shuomin Zhu,et al.  Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner , 2009, Oncogene.

[13]  Wei Li,et al.  Progesterone reverses the mesenchymal phenotypes of basal phenotype breast cancer cells via a membrane progesterone receptor mediated pathway , 2010, Breast Cancer Research.

[14]  Melanie Keppler,et al.  The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress , 2009, Nature.

[15]  H. Brauch,et al.  Common variants in the UBC9 gene encoding the SUMO‐conjugating enzyme are associated with breast tumor grade , 2009, International journal of cancer.

[16]  J. Xu,et al.  A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells. , 2009, International journal of oncology.

[17]  D. Coppola,et al.  Substantially reduced expression of PIAS1 is associated with colon cancer development , 2009, Journal of Cancer Research and Clinical Oncology.

[18]  Wonshik Han,et al.  CAMK1D amplification implicated in epithelial–mesenchymal transition in basal‐like breast cancer , 2008, Molecular oncology.

[19]  Ying-Ying Wei,et al.  TGF-beta1 increases motility and alphavbeta3 integrin up-regulation via PI3K, Akt and NF-kappaB-dependent pathway in human chondrosarcoma cells. , 2008, Biochemical pharmacology.

[20]  Gema Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[21]  G. Jeong,et al.  SUMO1 negatively regulates BRCA1-mediated transcription, via modulation of promoter occupancy , 2007, Nucleic acids research.

[22]  F. Gago,et al.  P-Cadherin and β-catenin are useful prognostic markers in breast cancer patients; β-catenin interacts with heat shock protein Hsp27 , 2008, Cell Stress and Chaperones.

[23]  D. Carson,et al.  MUC1 expression is repressed by protein inhibitor of activated signal transducer and activator of transcription-y. , 2007, Molecular endocrinology.

[24]  A. Rosenberg,et al.  Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients , 2007, Cancer.

[25]  Samy Lamouille,et al.  Cell size and invasion in TGF-β–induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway , 2007, The Journal of cell biology.

[26]  D. Jukic,et al.  SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas , 2007, Oncogene.

[27]  Jane Lee,et al.  The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor , 2007, Nucleic acids research.

[28]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[29]  J. Reis-Filho,et al.  Basal-like breast cancer and the BRCA1 phenotype , 2006, Oncogene.

[30]  S. H. Baek,et al.  A Novel Link Between SUMO Modification and Cancer Metastasis , 2006, Cell cycle.

[31]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Rostan,et al.  Sumoylation of the Estrogen Receptor α Hinge Region Regulates Its Transcriptional Activity , 2005 .

[33]  G. Owens,et al.  PIAS1 Activates the Expression of Smooth Muscle Cell Differentiation Marker Genes by Interacting with Serum Response Factor and Class I Basic Helix-Loop-Helix Proteins , 2005, Molecular and Cellular Biology.

[34]  Y. Mo,et al.  A role for Ubc9 in tumorigenesis , 2005, Oncogene.

[35]  E. Kremmer,et al.  PIASy-Deficient Mice Display Modest Defects in IFN and Wnt Signaling1 , 2004, The Journal of Immunology.

[36]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[37]  Kenichi Yokota,et al.  FHL2, UBC9, and PIAS1 are Novel Estrogen Receptor α‐Interacting Proteins , 2004 .

[38]  R. Honda,et al.  Sumoylation of Mdm2 by Protein Inhibitor of Activated STAT (PIAS) and RanBP2 Enzymes* , 2002, The Journal of Biological Chemistry.

[39]  S. Kaul,et al.  Ubc9 Is a Novel Modulator of the Induction Properties of Glucocorticoid Receptors* , 2002, The Journal of Biological Chemistry.

[40]  Ming You,et al.  Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  L. Bruhn,et al.  PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. , 2001, Genes & development.

[42]  H. Yasuda,et al.  Involvement of PIAS1 in the sumoylation of tumor suppressor p53. , 2001, Molecular cell.

[43]  N. Schechter,et al.  Ubc9 interacts with a nuclear localization signal and mediates nuclear localization of the paired-like homeobox protein Vsx-1 independent of SUMO-1 modification , 2001, Proceedings of the National Academy of Sciences of the United States of America.